A Bioequivalent Study to Compare Galantamine Oral Solution With Marketed Galantamine Capsule After Single Oral Administration of 10 mg.

Trial Profile

A Bioequivalent Study to Compare Galantamine Oral Solution With Marketed Galantamine Capsule After Single Oral Administration of 10 mg.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2010

At a glance

  • Drugs Galantamine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Xian-Janssen
  • Most Recent Events

    • 29 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top